Eli Lilly reached a market capitalization of $1 trillion on Friday, becoming the first pharmaceutical company to join the exclusive group previously dominated only by tech giants, Reuters reports.
The milestone reflects the company’s extraordinary rise, driven by soaring global demand for anti-obesity treatments — a sector that has rapidly evolved from niche to one of the most profitable categories in healthcare.
Eli Lilly’s shares have surged more than 35% in 2025, supported by the rapid expansion of the weight-loss drug market. Although Novo Nordisk pioneered the field, Lilly’s medications — Mounjaro and Zepbound — have gained increasing popularity for their strong clinical results.
Read full article here: turnovernews.com
Read also: Norofert officially opens its new production facility in Brazil
Photo: CTech
UK
IT
ES
DE
FR
RO
PT
HU
